title: Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C.
abstract: BACKGROUND
  Treatment of hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) has revolutionized the care of infected patients. Among these novel compounds are non-nucleoside analogs, which bind viral RNA-dependent RNA polymerase resulting in a conformational change inhibiting RNA synthesis.
  
  
  METHODS
  Efficacy and tolerability of treatment regimens containing the non-nucleoside analog polymerase inhibitor dasabuvir (ABT-333).
  
  
  CONCLUSIONS
  Dasabuvir-containing regimens achieve high rates of sustained virologic response in HCV genotype 1a and 1b-infected patients when combined with other DAAs, namely paritaprevir (ABT-450), ritonavir and ombitasvir (ABT-267). In the populations studied, dasabuvir seems to be well tolerated and safe. The major limitations of this novel drug are its genotype-restricted activity, the necessity to include ribavirin for HCV genotype 1a and the emergence of resistance if not combined with other DDAs.
authors: University of Miami/Jackson Memorial Hospital, Department of Gastroenterology and Hepatology , 1500 NW 12 Ave, Jackson Medical Tower E-1101, Miami, Fl 33136 , USA.
authors: Juan Pablo
authors: JP
authors: Trivella
authors: Julio
authors: J
authors: Gutierrez
authors: Paul
authors: P
authors: Martin
mesh_terms: D015081:2-Naphthylamine; D000813:Anilides / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D002219:Carbamates / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003521:Cyclopropanes; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000737:chemistry / Q000627:therapeutic use; D047029:Lactams, Macrocyclic; D047028:Macrocyclic Compounds / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000737:chemistry / Q000627:therapeutic use; D011392:Proline / Q000031:analogs & derivatives; D012324:RNA-Dependent RNA Polymerase / Q000378:metabolism; D012254:Ribavirin / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use*; D014498:Uracil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014633:Valine
chemical_list: D000813:Anilides; D000998:Antiviral Agents; D002219:Carbamates; D003521:Cyclopropanes; D016898:Interferon-alpha; D047029:Lactams, Macrocyclic; D047028:Macrocyclic Compounds; D013449:Sulfonamides; C586094:ombitasvir; D011092:Polyethylene Glycols; D012254:Ribavirin; D014498:Uracil; D011392:Proline; D015081:2-Naphthylamine; C588260:dasabuvir; D012324:RNA-Dependent RNA Polymerase; D014633:Valine; C585405:paritaprevir
keywords: ABT-333; antiviral agents; dasabuvir; hepatitis C; polymerase inhibitor; sustained virological response